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Abstract: Background: Maternal overweight and obesity is associated with 
well-recognised pregnancy complications. While antenatal dietary and 
lifestyle interventions modestly impact gestational weight gain with no 
effect on pregnancy outcomes, the role of metformin as an adjuvant 
therapy is unclear. 
Methods: Pregnant women at 10+0 to 20+0 weeks gestation with body mass 
index (BMI) ≥25kg/m2 were recruited from three public maternity units in 
South Australia. Women were randomised using a computer-generated 
schedule and received either metformin to a maximum dose of 2000mg per 
day, or an identical appearing placebo. All women received an antenatal 
dietary and lifestyle intervention. The primary outcome was the 
proportion of infants with birth weight >4000 grams. Statistical analyses 
adopted intention to treat principles. The trial was registered on the 
Australian and New Zealand Clinical Trials Registry 
(ACTRN12612001277831). A post-hoc analysis was performed to incorporate 
the trial findings in the current Cochrane Systematic Review and meta-
analysis.  
Findings: 524 women were randomised (261 Metformin; 263 Placebo). There 
was no significant difference in the proportion of infants with birth 
weight >4000 grams (15·63% Metformin versus 14·34% Placebo; adjusted Risk 
Ratio (aRR) 0·97; 95% Confidence Intervals (CI) 0·65-1·47; p=0·899). 
Women receiving metformin had lower average weekly gestational weight 
gain (GWG) (p=0·007), and were more likely to gain below recommendations 
(p=0·008). Total GWG, pregnancy and birth outcomes were not statistically 
significantly different. 
Update of the available Cochrane Systematic Review identified a modest 
impact on GWG, with no evidence of an impact on clinical pregnancy and 
birth outcomes.  
Interpretation: For pregnant women who are overweight or obese, metformin 
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Background: Maternal overweight and obesity is associated with well-recognised pregnancy 
complications. While antenatal dietary and lifestyle interventions modestly impact gestational 
weight gain with no effect on pregnancy outcomes, the role of metformin as an adjuvant 
therapy is unclear. 




 weeks gestation with body mass index (BMI) 
>25kg/m
2
 were recruited from three public maternity units in South Australia. Women were 
randomised using a computer-generated schedule and received either metformin to a 
maximum dose of 2000mg per day, or an identical appearing placebo. All women received an 
antenatal dietary and lifestyle intervention. The primary outcome was the proportion of 
infants with birth weight >4000 grams. Statistical analyses adopted intention to treat 
principles. The trial was registered on the Australian and New Zealand Clinical Trials 
Registry (ACTRN12612001277831). A post-hoc analysis was performed to incorporate the 
trial findings in the current Cochrane Systematic Review and meta-analysis.  
Findings: 524 women were randomised (261 Metformin; 263 Placebo). There was no 
significant difference in the proportion of infants with birth weight >4000 grams (15·63% 
Metformin versus 14·34% Placebo; adjusted Risk Ratio (aRR) 0·97; 95% Confidence 
Intervals (CI) 0·65-1·47; p=0·899). Women receiving metformin had lower average weekly 
gestational weight gain (GWG) (p=0·007), and were more likely to gain below 
recommendations (p=0·008). Total GWG, pregnancy and birth outcomes were not 
statistically significantly different. 
Update of the available Cochrane Systematic Review identified a modest impact on GWG, 
with no evidence of an impact on clinical pregnancy and birth outcomes.  
Interpretation: For pregnant women who are overweight or obese, metformin as an adjuvant 
to dietary advice does not improve pregnancy and birth outcomes.  
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The world-wide prevalence of overweight and obesity continues to climb.
1
 Across developed 





 placing both the woman and her infant at risk of a range of well-
documented adverse pregnancy and birth outcomes.
3
 Furthermore, high maternal BMI 
significantly predicts infant birth weight above 4000 grams, which in turn is recognised as an 




There has been considerable research and clinical interest in the provision of antenatal dietary 
and lifestyle interventions for pregnant women, particularly women who are overweight or 
obese, as a strategy to limit gestational weight gain (GWG), and thereby improve maternal 
pregnancy and birth, and infant outcomes. An individual participant data meta-analysis 
incorporating data from 36 randomised trials, and more than 12,500 pregnant women globally 
who received an antenatal dietary and/or lifestyle intervention
5
 indicates a modest effect on 
GWG (mean difference -0.7kg), but very little effect on clinical pregnancy outcomes,
5
 
findings consistent with other recent reports.
6
 Together these findings highlight the need for 
the evaluation of additional strategies. 
 
Metformin has been considered for use in pregnant women who are overweight or obese, 
recognising the associations between high maternal BMI and gestational diabetes, and a 
similar intrauterine milieu of insulin resistance, hyperglycaemia, hyperlipidaemia, and chronic 
inflammation.
7
 Metformin has insulin sensitising properties, reducing hepatic glucose 
production and increasing peripheral glucose utilisation,
8
 and is used increasingly in the 







 evaluating the use of metformin among obese pregnant women, have 
reported conflicting findings with regards to the effect on GWG and some pregnancy 
outcomes. Importantly, women participating in these randomised trials
10,11
 were not provided 
with a dietary and lifestyle intervention. Furthermore, as the risk of adverse pregnancy 
outcomes increases with increasing maternal BMI,
3
 there may be clinical benefit in providing 
treatment for women who are overweight, as well as for those who are obese. 
 
The aim of this randomised trial was to evaluate the effects of antenatal metformin as an 
adjuvant therapy to dietary and lifestyle advice among overweight and obese pregnant women 
on maternal and infant outcomes. 
 
Methods: 
Study Design and Participants 
Between June 2013 and April 2016, women were recruited from the three major public 
maternity hospitals in metropolitan Adelaide, South Australia. Eligible women had a live 




 weeks gestation, and were overweight (BMI 25·0-
29·9kg/m
2
) or obese (BMI >30·0kg/m
2
) at their first antenatal visit. Women with a multiple 
pregnancy, type 1 or 2 diabetes diagnosed prior to pregnancy, or with significant renal or 




 (Supplementary File 1) was approved by the Women's and Children's 
Health Network Human Research Ethics Committee with local institutional approval at each 
site, and registered on the Australian and New Zealand Clinical Trials Registry 
(ACTRN12612001277831). Participating women provided written informed consent. 
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Randomisation and Masking 
All women presenting for antenatal care at the participating centres had their height and 
weight measured, and BMI calculated at their first antenatal appointment. Eligible women 
were then counselled by a research assistant. Those women who consented to participate were 
randomised to the Metformin Group or Placebo Group, by using the central online 
randomisation service. The computer generated randomisation schedule utilised blocks of 
four, in the ratio 1:1, and was prepared by an investigator not involved with recruitment or 





), and collaborating centre.  
 
Metformin tablets 500 mg and identically appearing placebo tablets were packaged by an 
independent pharmaceutical packaging company (Pharmaceutical Packaging Professionals, 
Victoria) and coded according to the randomisation schedule. Women, their caregivers and 
research staff, including outcome assessors, were blinded to the allocated treatment 
(Metformin or Placebo).  
 
Procedures 
All women received a 16-week supply of tablets (metformin 500 mg or an identical appearing 
placebo), and a further 12-week supply at 28 weeks gestation. Women commenced tablets 
from randomisation, starting with one tablet daily for one week, and increasing to a maximum 
of two tablets twice daily (maximum dose metformin 2000 mg daily) over four weeks as 
tolerated, and then continuing until birth. 
 
At 36 weeks gestation, women completed a questionnaire to ascertain compliance with 
medication and the occurrence of any side effects.  
 8 
All women received dietary and lifestyle advice delivered over three face-to-face sessions 
(two with the dietitian, shortly after trial entry and at 28 weeks, and one with a research 
assistant at 36 weeks) and three telephone calls from the research assistant at 20, 24, and 32 
weeks. Dietary advice was consistent with Australian standards. Women were advised to 
maintain a balance of carbohydrates, fat and protein, while specifically encouraging a 
reduction in the intake of energy dense and non-core foods high in refined carbohydrates and 
saturated fats, increased intake of fibre, and consumption of two servings of fruit, five 




Tailoring of the intervention was informed by stage theories of health decision making.
15
 
Initially, there was a planning session with a research dietitian, in which women were 
provided with written information, an individual diet and physical activity plan, recipe book 
and example menu plans. Women were encouraged to set achievable goals for dietary and 
exercise change, supported to make these lifestyle changes and to self-monitor their progress, 
using a SMART (Specific, Measurable, Achievable, Relevant, and Timely)-goals approach. 
These principles were reinforced at subsequent face-to-face visits with the dietitian and 
research assistant, and during the telephone contacts.  
 
All women completed a food frequency questionnaire, exercise diary, and quality of life 
assessments at trial entry, 28 and 36 weeks gestation. Consistent with state-wide clinical 
practice guidelines, all women were screened for gestational diabetes at approximately 28 
weeks gestation.
16
 During the course of the trial, diagnostic criteria for gestational diabetes 
changed across the state from a positive 75g oral glucose tolerance test with fasting blood 
glucose >5·5mmol/L, or 2-hour ≥7·8mmol/L, to fasting blood glucose ≥5·1mmol/L, 1-hour 
≥10·0mmol/L, or 2-hour ≥8·5mmol/L.
16
 Women diagnosed with gestational diabetes 
 9 
remained in the study and were offered treatment with further dietary modification and 
metformin or insulin added as required to maintain appropriate glycaemic control.
16
 All other 





The primary outcome was the proportion of infants with birth weight above 4000 grams. 
 
A range of secondary outcomes were assessed, and included the following: 
1) Maternal weight gain outcomes including total GWG (defined as the difference between 
pregnancy weight obtained at 36 weeks gestation or nearest to birth and early pregnancy 
weight); average weekly GWG; and GWG below, within, or above the Institute of Medicine 
(IOM) recommendations according to early pregnancy BMI (defined as 7·0 to 11·5kg for 
women who were overweight and 5·0 to 9·0kg for women who were obese).
17
  
2) Maternal diet and physical activity as measured by questionnaires completed at trial entry, 
28 and 36 weeks gestation (using the Harvard Semi-quantitative Food Frequency 
Questionnaire,
18
 and the Short Questionnaire to Assess Health-enhancing physical activity)
19
. 
3) Maternal pregnancy and birth outcomes including hypertension (defined as a systolic 
blood pressure >140mmHg and / or diastolic >90mmHg on two occasions four or more hours 
apart) and pre-eclampsia (using the Australasian Society for the Study of Hypertension in 
Pregnancy criteria);
20
 clinical diagnosis of gestational diabetes;
16
 antepartum haemorrhage; 
preterm prelabour ruptured membranes; chorioamnionitis; induction of labour; caesarean 
section; postpartum haemorrhage (defined as blood loss >600 mL); perineal trauma; wound 
infection; endometritis; thromboembolic disease; and maternal death.  
4) Maternal quality of life and emotional wellbeing as measured by questionnaires completed 




 anxiety (Short Form Spielberger State Trait Inventory
22
) and 
depression (Edinburgh Postnatal Depression Scale
23
). 
5) Infant birth outcomes including preterm birth before 37 weeks; perinatal mortality (defined 
as either an intrauterine fetal death after trial entry, and after 20 weeks gestation but prior to 
birth, or the death of a live born infant prior to hospital discharge, and excluding lethal 
congenital anomalies); infant birth weight (including weight below 2500 grams, and weight 
above 4500 grams); large for gestational age (defined as weight above the 90th centile for 
gestational age and infant sex); small for gestational age (defined as weight below the 10th 
centile for gestational age and infant sex); hypoglycaemia requiring treatment; infant 
admission to the neonatal intensive care unit, or special care baby unit; hyperbilirubinaemia 
requiring phototherapy; nerve palsy; fracture; birth trauma; shoulder dystocia; and newborn 
anthropometric measures (including biceps, triceps, abdominal, suprailiac, subscapular and 
thigh skinfold thicknesses, and head, chest, abdominal and right upper arm circumferences 
taken within the first days after birth according to a specifically developed protocol).
24
  
6) Fetal growth and adiposity measures determined by ultrasound at 28 and 36 weeks 
gestation. 
7) Costs of health care to determine the cost of the intervention per live birth. 
 
Sample size 
The primary clinical outcome was the proportion of infants born with birth weight above 
4000 grams, which was estimated to occur in 15.5% of women eligible for this trial.
13
 To 
detect a 47% difference from 15.5% to 7.35% (alpha 0.05; power 80%),
13
  and accounting for 
a 5% rate of attrition (based on our experience with the LIMIT Study), we estimated a sample 




All analyses followed a pre-specified statistical analysis plan (Supplementary File 2). 
Baseline characteristics of all randomised women were examined descriptively as an 
indication of comparable treatment groups, and included maternal age, parity, race, height, 
weight, smoking status, past obstetric history, and a diagnosis of previous gestational 
diabetes. Primary and secondary outcomes were analysed on an “intention to treat” basis, 
according to the treatment allocated (Metformin or Placebo) at the time of randomisation. 
Continuous outcomes were analysed using linear regression, and binary outcomes were 
analysed using log binomial regression. Outcomes measured at multiple time points included 
a time-by-treatment interaction term, with Generalised Estimating Equations used to account 
for correlation between repeated measures. 
 
As specified in the Statistical Analysis Plan (Supplementary File 2), the primary analyses 
were adjusted analyses based on imputed data. Unadjusted analyses, and analyses on 
unimputed data (not presented), were also performed as secondary sensitivity analyses. 
Adjusted models included the stratification variables (centre, maternal BMI, and parity) as 
well as smoking, socio-economic status (as indicated by the Australian Bureau of Statistics’ 
2011 Socio-economic Index for Areas – Index of Relative Socio-economic Disadvantage 
(SEIFA IRSD) quintile), and maternal age at trial entry as covariates. 
 
There were no missing values for the primary outcome or for other infant birth weight 
outcomes; many other outcomes (including infant anthropometry, infant and maternal 
delivery data) had less than 1% missing data, while infant SFTM and other maternal antenatal 
measures had between 20%-40% missing data. Multiple imputation by the fully conditional 




 The imputation model included all outcomes, all stratification variables, maternal 
baseline height, weight and gestational age, and maternal weight at 36 weeks gestation. 
Estimates were derived in the standard manner by combining the estimates from each 
imputation using Rubin’s Rules.
25
 As there were no missing values for the primary outcome, 
no missing not at random (MNAR) sensitivity analyses were performed. Analyses were 
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata version 14 
(StataCorp, Texas, USA). 
 
Meta-analysis 
Our published Cochrane Systematic Review adhered to standard Cochrane methodology.
26
 In 
brief, randomised and quasi-randomised trials evaluating metformin use (compared with 
placebo or no metformin) in pregnant women who were overweight or obese, defined as an 
early or pre-pregnancy BMI >25.0kg/m
2
 were identified and considered after searching the 
Cochrane Pregnancy and Childbirth's Trials Register. Two review authors independently 
assessed risk of bias for each study, with statistical analyses conducted using the Review 
Manager 5 software. A fixed‐effect meta‐analysis was used to combine data where trials were 
judged to be sufficiently similar, and a random-effects meta-analysis to produce an overall 
summary if substantial statistical heterogeneity was detected. For dichotomous data, results 
are presented as summary risk ratio (RR) with 95% CIs, while for continuous data, the mean 
difference (MD) was calculated. Available data from the GROW randomised trial were 
incorporated into the available published systematic review and meta-analysis.  
 
Role of the funding source 
The funder had no role in the study design, data collection, analysis, interpretation, or writing 
of the report. The corresponding author had full access to the data and final responsibility for 
 13 
the decision to submit for publication. 
 
Results: 
Between June 2013 and April 2016, 3,546 eligible women were approached to participate, 
with 524 randomised, 261 (49·8%) to Metformin and 263 (50·2%) to Placebo (Figure 1). A 
total of 514 women and infants were included in the analyses. There were no maternal deaths. 
There were two stillborn infants, both in the placebo group, one secondary to acute 
chorioamnionitis, and the other due to early onset fetal growth restriction and pre-eclampsia. 
There was one neonatal death in the metformin group following extremely preterm birth.  
 
The baseline characteristics of women in the two treatment groups were similar at trial entry 
(Table 1). The median BMI of the cohort was 32·32kg/m
2
 (Inter-Quartile Range (IQR) 28·90 
to 37·10kg/m
2
), with 32·49% of women overweight, and 67·51% obese. Adequate data were 
available for 514 (100%) infants for the primary outcome of birth weight above 4000 grams.  
 
Over 77% of participants completed the questionnaire assessing compliance with medication 
(Table S1) and experience of side effects (Table 2), with no differences between the two 
treatment groups. Of women who responded, almost 84% took the maximum of 4 tablets 
daily, with approximately 75% of women in both treatment groups reporting the occurrence 
of one or more side effects, most commonly fatigue, nausea or diarrhoea.  
 
There was no statistically significant difference in the proportion of infants with birth weight 
above 4000 grams between the Metformin and Placebo groups (40/256 (15·63%) Metformin 
versus 37/258 (14·34%) Placebo; adjusted risk ratio (aRR) 0·97; 95% confidence interval 
(CI) 0·65 to 1·47; p=0·899) (Table 3).  
 14 
Women who received metformin when compared with women who received placebo, had 
lower average weekly GWG (0·38 + 0·34 kg Metformin vs 0·47 + 0·35 kg Placebo; aMD -
0·08; 95% CI -0·14 to -0·02; p=0·007), and were more likely to have weight gain below the 
IOM recommendations (100 (39·20)% Metformin versus 70 (27·00%) Placebo; aRR 1·46; 
95% CI 1·10 to 1·94; p=0·008) (Table 4). Total GWG was not statistically significantly 
different between the treatment groups (7·48 + 6·95 kg Metformin versus 8·72 + 6·91 kg 
Placebo; aMD -1·18; 95% CI -2·37 to 0·01; p=0·053). Dietary patterns and physical activity 
(Table S2) also did not differ between the two treatment groups at trial entry or over the 
course of pregnancy. 
 
There were no statistically significant differences between the two treatment groups with 
regards to maternal risk of pregnancy (Table 4) complications, particularly a diagnosis of 
gestational diabetes, regardless of the diagnostic criteria used (Table S3). Furthermore, 
following diagnosis, there were no statistically significant differences between the treatment 
groups with regards use of either metformin or insulin therapy (Table S3).  
 
The risks of maternal labour complications (Table 5) were not significantly different between 
the two treatment groups. While there was a reduction in risk of caesarean birth among 
women administered metformin as compared with placebo (87 (33·98%) Metformin versus 
111 (43·02%) Placebo; aRR 0·78; 95% CI 0·62 to 0·97; p=0·025), this likely reflected 
differences in the number of women undergoing an elective repeat caesarean birth (44 
(17·19%) Metformin versus 54 (20·93%) Placebo; aRR 0·72; 95% CI 0·52 to 1·00; p=0·053) 
(Table 5). Self-reported maternal quality of life did not differ between groups (Table S4). 
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The mean gestational age at birth was similar between the two groups (39·12 + 1·64 weeks 
Metformin versus 38·93 + 1·85 weeks Placebo; aMD 0·10; 95% CI -0·20 to 0·40; p=0·532), 
as was mean infant birth weight (3487·80 + 531·37 grams Metformin versus 3471·80 + 
556·67 grams Placebo; aMD -13·01; 95% CI -106·45 to 80·44; p=0·785) (Table 3). There 
were no statistically significant differences between the two groups with regards to other 
infant outcomes (Table 3) or newborn anthropometric measures (Table S5). Although infant 
abdominal circumference at birth was 0·5cm smaller in the Metformin group (33·35 + 2·72 
cm Metformin versus 33·74 + 2·87 cm Placebo; adjusted mean difference -0·48; 95% CI -
0·97 to -0·00; p=0·049) this is likely a chance finding and the small difference of 
questionable clinical significance (Table S5).  
 
A pre-specified secondary analysis identified some evidence of effect modification by 
maternal BMI category, the use of metformin being associated with a greater reduction in the 
proportion of infants with birth weight above 4000 grams, and a reduction in total GWG, 
among overweight, when compared with obese women (Table S6). 
 
Fetal growth and adiposity measures determined by ultrasound will be reported in a 
subsequent manuscript. A detailed health economics cost analysis was not performed given 
that the intervention demonstrated no significant impact on clinical outcomes.  
 
Meta-analysis 
In a post-hoc analysis incorporating the findings of the GROW trial in the published 
Cochrane Systematic Review,
26
 metformin was identified to have only a modest impact on 
GWG (Mean Difference -2·27 kg; 95% CI -4·45 to -0·08; 4 studies; 1,278 women). There 
 16 
was no evidence of an impact on clinical pregnancy and birth outcomes, and particularly the 
risk of pre-eclampsia (RR 0·82; 95% CI 0·25 to 2·68; 3 studies; 1,355 women).  
 
Discussion: 
In our randomised trial, overweight or obese pregnant women who received metformin as an 
adjuvant therapy to dietary and lifestyle advice did not significantly differ in the chance of 
their infant having birth weight above 4000 grams, when compared with women who 
received placebo and dietary and lifestyle advice. Although there were no statistically 
significant differences in total GWG, women who received metformin were more likely to 
have weight gain below the IOM recommendations, and have lower average weekly GWG. 
However, these differences in GWG were not accompanied by a significant effect on maternal 
and infant pregnancy or birth outcomes.  
 
Our randomised trial has a number of strengths, being the first to include both overweight and 
obese women, as the risk of adverse pregnancy outcomes increases with increasing maternal 
BMI. We utilised robust methods, including prospectively measured height, weight, and BMI 
in all participants, central randomisation, and appropriate blinding of participants, clinicians 
and outcome assessors. Furthermore, we had pre-specified outcomes of clinical relevance, 
followed a pre-specified analysis plan, and achieved a high rate of follow-up of participants. 
 
Our trial is also the first to evaluate the effect of metformin as an adjuvant therapy to an 
antenatal dietary and lifestyle intervention. Following dietary intervention over the course of 
pregnancy, women across both treatment groups were successful in modifying their dietary 
intake, specifically reducing their overall energy intake and improving their healthy eating 
index score as an indicator of diet quality. These findings are consistent with those reported 
 17 
previously from the LIMIT randomised trial,
13,27
 highlighting the reproducibility of the 
intervention among overweight and obese pregnant women in producing dietary change. 
Together, these findings also suggest that many of the complex determinants of GWG may 
not be readily modifiable by changes to dietary intake and physical activity.  
 
Our trial population was predominantly white Caucasian and from the highest areas of social 
disadvantage, with approximately 85% of eligible women declining to participate due to time 
constraints and lack of willingness to take medication during pregnancy. Together, these 
findings limit somewhat our generalisability and external validity. However, such rates of 
uptake of trial participation (15%) are within the range described by similar trials in the 




Our estimates of compliance indicate 84% of respondents took the maximum of 4 tablets 
daily, with no differences identified between the treatment groups. These figures are difficult 
to directly compare with other studies, which have used varying measures to assess treatment 
compliance,
10,11
 although our assessment of adherence is comparable to the overall 80% 
reported by Syngelaki and colleagues,
11




While metformin is increasingly used in pregnancy for the treatment of gestational diabetes,
9
 
and there is evidence to support its safety, longer-term childhood follow-up of the offspring of 
women who participated in this trial will be important. The primary findings from the MIG 
trial did not identify any differences in infant birth weight for women with GDM who were 
treated with insulin, as compared with metformin.
9
 However, follow-up of child participants 
at 9 years of age indicates children exposed to metformin, as compared with insulin, were of 
 18 
higher weight and BMI, with some suggestion of increased adipose tissue deposition 




As highlighted in our methods, during the course of the trial there was a change in the 
diagnostic criteria for GDM across the State.
16
 However, the criteria were applied equally 
across the two treatment groups, and we demonstrated no significant differences in diagnosis 
or requirements for metformin or insulin between the two treatment groups. While the change 
in criteria may have resulted in an increase in the number of women being diagnosed with 
GDM, discussion of the relative merits and evidence base to support a range of different 
testing approaches and criteria is well beyond the focus and scope of this manuscript. 
 
Our findings do not suggest that metformin impacts clinical pregnancy and birth outcomes, 
which is broadly consistent with the available literature.
10,11,29
 Syngelaki and colleagues 
reported a significant reduction in the risk of pre-eclampsia following metformin 
administration. This was not evident when the current trial data are incorporated in the 
available published meta-analysis (RR 0·82; 95% CI 0·25 to 2·68; 3 studies; 1,355 women),
26
 
raising the possibility of a spurious finding of a secondary outcome. 
 
We did not identify a statistically significant reduction in total GWG, although there was 
some evidence of effect modification, with a possible greater benefit from metformin in 
reducing the risk of infant birth weight above 4000 grams, and total GWG among overweight, 
as compared with obese women. While this secondary analysis was pre-specified, our 




Our findings in relation to GWG are consistent with those of Chiswick,
10
 but in contrast to 
those of Syngelaki
11
 and Abd El Fattah.
29
 Incorporation of our data into the Cochrane 
Systematic Review
26
 indicates overall, metformin has a very modest impact on GWG (Mean 
Difference -2·27 kg; 95% CI -4·45 to -0·08; 4 studies; 1,278 women). While there are 
inherent variations in the study design of the randomised trials evaluating metformin 
conducted to date,
10,11,29
 including the BMI of women recruited (overweight and obese in the 
current trial versus obese only
10,11,29
), the dose of metformin administered (1000mg
29
 up to 
3000mg
11
 daily), and the inclusion of a dietary and lifestyle intervention for all women in the 
current trial, these differences appear insufficient to explain the overall observations of a 
limited reduction in GWG and lack of effect on clinical outcomes. 
 
Such a limited effect of metformin is, however, consistent more broadly with the evidence 
relating to prenatal dietary and lifestyle interventions
5
 for women who are overweight or 
obese, and raises important questions as to their modest at best reduction in GWG, and little 
evidence of effect on clinical outcomes. It is important to recognise that the IOM 
recommendations
17
 are based on extensive observational literature identifying associations 
between GWG and pregnancy outcomes, with an underlying assumption that the observed 
associations are causal in nature. Furthermore, it has been assumed that GWG can be 
modified either through use of metformin, or via changes to diet and lifestyle during 
pregnancy, and that weight gain within the recommended range leads to optimal maternal and 
infant outcomes.  
 
These prevailing assumptions need to be questioned in light of the mounting available clinical 
evidence from randomised trials. For pregnant women who are overweight or obese, 
intervention during pregnancy (whether through metformin, dietary or lifestyle modification, 
 20 
or a combination of the two) may be “too little, too late”, highlighting the need to target 
women, particularly those who are overweight or obese, prior to conception to improve their 
diet and lifestyle, and to encourage weight loss.
30
 Not withstanding the logistical implications 
of intervention prior to conception, there is currently little evidence to support improved 
pregnancy outcomes following pre-conception weight loss, and robust evaluation of such an 
approach is urgently required.  
 
Our findings indicate that the use of metformin as an adjuvant to a dietary and lifestyle 
intervention among pregnant women who are overweight or obese was associated with some 
evidence of reduced GWG measures, but did not impact clinical pregnancy and birth 
outcomes. Use of metformin in this clinical setting is not advocated. 
  
 21 
Panel: Research in context 
Evidence before this study 
Antenatal dietary and lifestyle interventions for pregnant women, particularly those who are 
overweight or obese, have been evaluated as a strategy to limit gestational weight gain but 
demonstrate only a modest effect on weight gain in pregnancy and very little effect on clinical 
outcomes.  
Metformin has been proposed as a possible agent for use among obese pregnant women, 
although recent studies have reported conflicting findings with regards to the effect on GWG 
and some pregnancy outcomes. Importantly, women participating in these randomised trials 
were not provided with a dietary and lifestyle intervention. Furthermore, as the risk of adverse 
pregnancy outcomes increases with increasing maternal BMI, there may be clinical benefit in 
providing treatment for women who are overweight, as well as for those who are obese.  
 
Added value of this study 
To our knowledge, this is the first trial to evaluate the effect of metformin as an adjuvant 
therapy to an antenatal dietary and lifestyle intervention, and to include women both who are 
overweight or obese. 
 
Implications of all of the available evidence 
The use of metformin as an adjuvant therapy to an antenatal dietary and lifestyle intervention 
in women who are overweight or obese did not impact the chance of infant birth weight above 
4000 grams. There was no effect of metformin on total gestational weight gain or other 
clinical pregnancy and birth outcomes. The use of metformin in this clinical setting is not 
 22 
advocated, and future strategies should focus on improving women’s health and diet to 
encourage weight loss prior to conception.  
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3,546 Eligible women 
approached to participate 
3,013 Women declined to 
participate 
 
20% Concerned about taking 
medication during pregnancy 
19% Not interested  
18% Too busy/other commitments 
17% Unable to contact  
15% No reason provided 
 
524 Women provided 
written consent and were 
randomised 
261 (49·8%)  
Women randomised to  
Metformin Group 
263 (50·2%)  
Women randomised to  
Placebo Group 
0 woman withdrew consent 
5 women miscarriage before 20 weeks or 
termination of pregnancy 
0 women suffered stillbirth after 20 weeks 
256 live born infants 
1 neonatal death 
0 maternal death 
 
1 woman withdrew consent 
2 women miscarriage before 20 weeks or 
termination of pregnancy 
2 women suffered stillbirth after 20 weeks 
258 live born infants 
0 neonatal deaths 
0 maternal death 
 
256 Women  
and 
Infants 





included in the analysis 
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29·87 (5·54) 30·17 (5·37) 
Study Centre
#
   
.  Womens and Childrens Hospital 110 (42.97) 112 (43.41) 
.  Lyell McEwin Hospital 117 (45.70) 118 (45.74) 
.  Flinders Medical Centre 29 (11.33) 28 (10.85) 














Body Mass Index Category
# 
  
.  BMI 25.0-29.9 kg/m
2
 83 (32·42) 84 (32·56) 
.  BMI >30.0 kg/m
2
 173 (67·58) 174 (67·44) 
Public Patient
# 
252 (98·44) 254 (98·45) 
Weight (kg)
* 
92·89 (19·76) 91.80 (19·79) 
Height (cm)
* 




.  Caucasian 210 (82·03) 221 (85·66) 
.  Asian 5 (1·95) 7 (2·71) 
.  Indian 12 (4·69) 6 (2·33) 
.  Other 29 (11·33) 17 (9·30) 
Smoker
# 









88 (34·38) 92 (35·66) 
Previous Preterm Birth
# 
13 (5·08) 13 (5·04) 
Previous Pre-eclampsia
# 
13 (5·08) 10 (3·88) 
Previous Stillbirth or Neonatal Death
# 
1 (0·39) 6 (2·33) 
Previous Caesarean Section 48 (18·75) 67 (25·97) 
Family History of Diabetes
# 
83 (32·42) 78 (30·23) 
Family History of Hypertension
# 
105 (41·02) 104 (40·31) 
Family History of Heart Disease
# 
58 (22·66) 61 (23·64) 
Index of Socio-economic Disadvantage^   
.  Quintile 1 (Most Disadvantaged) 76 (29·69) 95 (36·82) 
.  Quintile 2 78 (30·47) 74 (28·68) 
.  Quintile 3 31 (12·11) 30 (11·63) 
.  Quintile 4 52 (20·31) 43 (16·67) 
.  Quintile 5 (Least Disadvantaged) 19 (7·42) 16 (6·20) 
 
*= mean and standard deviation 
+
= median and interquartile range 
#
= number and % 
^= Socioeconomic index of relative social disadvantage as measured by SEIFA 
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**=Includes all women randomised who did not withdraw consent to use their data, and who did not suffer miscarriage or termination of 










Overall Respondents 194 204 
Experience of one or more side effects 140 (72·16) 158 (77·45) 
 - Nausea 65 (33·51) 73 (35·78) 
 - Vomiting 48 (24·74) 46 (22·55) 
 - Abdominal Pain 49 (25·26) 47 (23·04) 
 - Diarrhoea 52 (26·80) 52 (25·49) 
 - Fatigue 87 (44·85) 101 (49·51) 
 - Weakness 27 (13·92) 36 (17·65) 
 - Skin Rash 17 (8·76) 16 (7·84) 
 - Loss of Appetite 43 (22·16) 43 (21·08) 
 
**Includes all women randomised who did not withdraw consent to use their data, and who did not suffer miscarriage or termination of 
pregnancy prior to 20 weeks gestation, or stillbirth 















 Effect (95% CI) 
Unadjusted     
P-value 
Adjusted Treatment  
Effect (95% CI) 
Adjusted  
P-value 
Birth weight above 4000g
# 
40 (15·63) 37 (14·34) 1·09 (0·72, 1·65) 0·684 0·97 (0·65, 1·47) 0·899 
Birth weight (grams)
~ 
3487·80 (531·37) 3471·80 (556·67) 16·00 (-78·10, 110·09) 0·739 -13·01 (-106·45, 80·44) 0·785 
Gestational Age at birth (weeks)
~ 
39·12 (1·64) 38·93 (1·85) 0·19 (-0·11, 0·49) 0·222 0·10 (-0·20, 0·40) 0·532 
Large for Gestational Age
# 
50 (19·53) 56 (21·71) 0·90 (0·64, 1·26) 0·543 0·87 (0·62, 1·23) 0·428 
Small for Gestational Age
# 
10 (3·91) 8 (3·10) 1·26 (0·51, 3·14) 0·620 1·37 (0·55, 3·45) 0·502 
Birth weight above 4500g
# 
5 (1·95) 7 (2·71) 0·72 (0·23, 2·24) 0·570 0·64 (0·21, 1·97) 0·433 
Birth weight below 2500g
# 
4 (1·56) 11 (4·26) 0·37 (0·12, 1·14) 0·082 0·42 (0·13, 1·31) 0·135 
Stillbirth
#
^ 0 (0·00) 2 (0·77) --  -- 0·499^ 
Neonatal Death
#
^ 1 (0·39) 0 (0·00) --  -- 0·496^ 
Admission to NICU or SCBU
# 









16 (6·27) 20 (7·75) 0·81 (0·43, 1·53) 0·513 0·76 (0·41, 1·40) 0·379 
Nerve Palsy
#
+ 0 (0·00) 0 (0·00) --  --  
Fracture
#
^ 1 (0·39) 0 (0·00) --  -- 0·497^ 
Birth Trauma
#
^ 3 (1·18) 0 (0·00) --  -- 0·122^ 
Shoulder Dystocia
# 
7 (2·73) 7 (2·71) 1·01 (0·36, 2·83) 0·988 0·96 (0·34, 2·66) 0·935 
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**Includes all women randomised who did not withdraw consent to use their data, and who did not suffer miscarriage or termination of 
pregnancy prior to 20 weeks gestation, or stillbirth 
#
 Number and percentage 
~
 Mean and SD 
* Poisson model with robust variance estimation used for adjusted analysis as binomial model did not converge 
^ Insufficient events for analysis or imputation.  p value from Fishers Exact test on un-imputed data. 
+ There were no events in either group so no modelling was possible  
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Unadjusted Treatment  
Effect (95% CI) 
Unadjusted 
P-value 
Adjusted Treatment  
Effect (95% CI) 
Adjusted 
 P-value 
Total Gestational Weight Gain (kg)
~
* 7·48 (6·95) 8·72 (6·91) -1·23 (-2·45, -0·01) 0·048 -1·18 (-2·37, 0·01) 0·053 
Average Weekly Gestational Weight Gain (kg)
~ 
0·38 (0·34) 0·47 (0·35) -0·08 (-0·14, -0·02) 0·006 -0·08 (-0·14, -0·02) 0·007 
Gestational Weight Gain Below 
Recommendations
# 
100 (39·20) 70 (27·00) 1·45 (1·09, 1·93) 0·010 1·46 (1·10, 1·94) 0·008 
Gestational Weight Gain Above 
Recommendations
# 
83 (32·27) 101 (39·10) 0·83 (0·64, 1·07) 0·145 0·84 (0·65, 1·09) 0·185 
Preterm birth before 37 weeks gestation
#
* 13 (5·08) 18 (6·98) 0·73 (0·36, 1·45) 0·368 0·79 (0·40, 1·58) 0·504 
Hypertension
#
* 19 (7·42) 16 (6·23) 1·19 (0·63, 2·26) 0·592 1·25 (0·66, 2·35) 0·496 
Pre-Eclampsia
#
* 13 (5·08) 11 (4·28) 1·19 (0·54, 2·60) 0·667 1·22 (0·56, 2·66) 0·618 
Gestational Diabetes
# 
72 (27·93) 62 (23·95) 1·17 (0·85, 1·60) 0·335 1·19 (0·88, 1·62) 0·253 
Antenatal Admission
# 
48 (18·75) 62 (24·03) 0·78 (0·56, 1·09) 0·146 0·82 (0·59, 1·15) 0·254 
Antepartum Haemorrhage Requiring Admission
# 
1 (0·39) 7 (2·69) --  -- 0·068^ 
Preterm Prelabour Ruptured Membranes
#
^ 5 (1·95) 3 (1·15) --  -- 0·502^ 
 
* Poisson model with robust variance estimation used for adjusted analysis as binomial model did not converge 
^ Insufficient events for analysis or imputation.  p value from Fishers Exact test on un-imputed data. 
**Includes all women randomised who did not withdraw consent to use their data, and who did not suffer miscarriage or termination of 
pregnancy prior to 20 weeks gestation, or stillbirth 
# 
Number and percent 
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~ 
Mean and SD  
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Unadjusted Treatment  
Effect (95% CI) 
Unadjusted  
P-value 
Adjusted Treatment  
Effect (95% CI) 
Adjusted  
P-value 
Chorioamnionitis  3 (2·22) 5 (3·40) --  -- 0·725^ 
Induction of Labour
 
104 (40·63) 87 (33·72) 1·20 (0·96, 1·51) 0·107 1·19 (0·95, 1·49) 0·139 
Antibiotics During Labour
 
135 (52·73) 147 (56·98) 0·93 (0·79, 1·08) 0·334 0·95 (0·81, 1·11) 0·493 
Caesarean Section – All
 
87 (33·98) 111(43·02) 0·79 (0·63, 0·99) 0·037 0·80 (0·64, 1·00) 0·049 
Elective Caesarean Section
 
44 (17·19) 54 (20·93) 0·82 (0·57, 1·18) 0·281 0·72 (0·51, 1·00) 0·053 
Emergency Caesarean Section
 
43 (16·80) 57 (22·09) 0·76 (0·53, 1·09) 0·131 0·79 (0·56, 1·11) 0·168 
Postpartum Haemorrhage Above 600mls
 
66 (25·79) 58 (22·55) 1·14 (0·84, 1·56) 0·393 1·15 (0·85, 1·57) 0·367 
3rd/4th Degree Perineal Trauma
 
6 (2·34) 3 (1·15) --  -- 0·336^ 
Wound Infection
 
3 (1·17) 3 (1·16) --  -- >0·999^ 
Endometritis
 
3 (1·17) 3 (1·16) --  -- >0·999^ 
Thromboembolic Disease
 
1 (0·39) 0 (0·00) --  -- 0·497^ 
 
**Includes all women randomised who did not withdraw consent to use their data, and who did not suffer miscarriage or termination of 
pregnancy prior to 20 weeks gestation, or stillbirth 
*Poisson model with robust variance estimation used for adjusted analysis as binomial model did not converge  
All values presented are number and percent 
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